期刊文献+

抗高血压候选药物ATPT在比格犬体内的药代动力学 被引量:1

Pharmacokinetics of a novel antihypertension candidate ATPT in Beagle dogs
在线阅读 下载PDF
导出
摘要 采用LC-MS/MS方法对ATPT在比格犬体内的药代动力学特征进行了研究。结果表明,比格犬单次灌胃给予ATPT混悬液后,ATPT在比格犬体内的药代动力学行为符合二房室模型特征;ATPT在比格犬体内吸收迅速,并且达峰后消除迅速,3个剂量组(7.5,15,30 mg/kg)的tmax和t1/2分别为0.7~1.0 h和3.5~4.3 h;3个剂量组的AUC0-∞分别为(5 465.9±1 748.7)、(7 846.2±3 547.4)和(15 490.9±8 292.4)ng.h/mL,AUC0-∞与剂量间呈良好的线性关系,呈线性动力学过程;经过剂量校正,求得ATPT在比格犬体内的绝对生物利用度分别为39.7%、28.5%和28.1%。 An LC-MS/MS method was used for the evaluation of a novel antihypertension candidate pharmacokinetics of ATPT in Beagle dogs.After ig administration of 7.5,15 and 30 mg/kg ATPT,the determined tmax and t1/2 of ATPT in dogs were 0.7-1.0 h and 3.5-4.3 h,respectively.While the areas under the curve(AUC0-∞) were(5 465.9±1 748.7),(7 846.2±3 547.4) and(15 490.9±8 292.4) ng ·h/mL at three doses,respectively.Good linearity was observed between cmax/AUC0-∞ and dose(R20.98) after a single ig administration of 7.5,15 and 30 mg/kg in dogs.After adjustment of dose,the absolute bioavailabilities of ATPT in dogs were 39.7%,28.5% and 28.1%,respectively.It presented a linear pharmacokinetics for ATPT in Beagle dogs within the dose range of the study.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2013年第2期151-155,共5页 Journal of China Pharmaceutical University
基金 国家"重大新药创制"科技重大专项资助项目(No.2009ZX09304-001 No.2009ZX09102-036) 中央高校基本科研业务费专项资金资助项目(No.JKP2009007)~~
关键词 ATPT 抗高血压药物 AT1受体拮抗剂 LC-MS MS 药代动力学 ATPT antihypertension candidate angiotensin II type 1 receptor antagonist LC/MS/MS pharmacokinetics
  • 相关文献

参考文献6

二级参考文献42

共引文献17

同被引文献13

  • 1Huttunen KM, Raunio H, Rautio J. Prodrugs--from serendipity to rational design [ J ]. Pharmacol Rev ,2011,63 ( 3 ) :750 - 771.
  • 2Zawilska JB, Wojcieszak J, Olejniczak AB. Prodrugs : a challenge for the drug development [ J ]. Pharmaeol Rep, 2013,65 ( 1 ) : 1 -14.
  • 3Stella VJ. Prodrugs : some thoughts and current issues [ J ]. J Pharm Sci ,2010,99( 12 ) :4 755 -4 765.
  • 4Scott 17I, Osterman MT. Medical management of Crohn disease [J]. Clin Colon Rectal Surg ,2013 ,26 ( 2 ) :67 -74.
  • 5Papi C, Fasci SF, Margagnoni G, et al. Randomized controlled tri- als in prevention of postsurgical recurrence in Crohn's disease [J]. Rev Recent Clin Trials,2012,7(4) :307 -413.
  • 6Jana S, Mandlekar S, Marathe P. Prodrug design to improve phar- macokinetic and drug delivery properties: challenges to the discovery scientists [ J ]. Curt Med Chem, 201 O, 17 ( 32 ) : 3 874 - 3 908.
  • 7Marat DM, Romari Am, Mariela N ,et al. Biomarkers of genotoxic- ity and genomie instability in a non-human primate, Cebus libidi- nosus ( Cebidae, Platyrrhini ), exposed to nitroimidazole deriva- tives[J]. Mutat Res ,2011,721( 1 ) : 108 - 113.
  • 8Menendez D, Rojas E, Herrera LA, et al. DNA breakage due to metronidazole treatment [ J ]. Mutat Res, 2001,478 ( 1/2 ) : 153 - 158.
  • 9Muller J, Schildkneeht P, Muller N. Metabolism of nitro drugs metronidazole and nitazoxanide in Giardia lamblia:characteriza- tion of a novel nitroreductase (G1NR2) [ J ]. J Antimicrob Chemother,2013,68 ( 8 ) : 1 781 - 1 789.
  • 10Lopez NMM, Palermo AM, Mudry MD, et al. Cytogenetie evalua- tion of two nitroimidazole derivatives[J]. Toxicol In Vitro,2003, 17(1) :35 -40.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部